|
|
Article: The Alliance for Better Bone Health Responds to Fosamax Actonel Comparison Trial Results.
- Article from:
- Business Wire
- Article date:
- September 28, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BRIDGEWATER, N.J. & CINCINNATI -- The Alliance for Better Bone Health announced its response to the results of Merck's bone mineral density (BMD) study released today.
"Bone mineral density (BMD) is important for determining if a patient needs therapy, but when determining which therapy, fracture reduction is the clinically relevant endpoint," says Dr. Nora Zorich, M.D., Ph.D., Head of Drug Development, P&G Pharmaceuticals. "If Merck had intended to fully compare efficacy, they would have run a head-to-head fracture trial."
Merck's own vice president of clinical research was quoted to this effect in response to another comparative BMD trial, "People ...